Trevi Therapeutics price target raised to $21 from $11 at Clear Street

Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $21 from $11 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3 report. Trevi has completed the requirements for an end of Phase 2 meeting with the FDA and plans to request the meeting in Q4 to finalize its Phase 3 program in idiopathic pulmonary fibrosis-related chronic cough, the analyst tells investors in a research note. Clear cites regulatory path clarity for the target increase.